Welcome to our dedicated page for Petros Pharmaceuticals SEC filings (Ticker: PTPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Petros Pharmaceuticals, Inc. (PTPI) provide detailed insight into the company’s technology-focused strategy, capital structure, and listing status. Through its periodic and current reports, investors can review how Petros describes its shift toward a SaaS and Software-as-a-Medical-Device (SaMD) platform designed to support prescription-to-over-the-counter (Rx-to-OTC) switches under U.S. Food and Drug Administration (FDA) guidance, including the "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" (ACNU) framework.
On this page, users can access Forms 10-K and 10-Q for information about Petros’ financial condition, discontinued operations, and deconsolidation of former subsidiaries such as Metuchen Pharmaceuticals LLC, Timm Medical Technologies, Inc., and Pos-T-Vac, LLC. These reports explain how the company classified those operations as discontinued and moved to deconsolidate their assets, liabilities, and equity from its consolidated balance sheet, as well as the impact of assignments for the benefit of creditors and license terminations.
Form 8-K current reports are particularly important for tracking material events. Petros has used 8-K filings to disclose notice of delisting from the Nasdaq Stock Market, the suspension of trading on Nasdaq and subsequent trading on OTC markets under the symbol PTPI, and Nasdaq’s intention to file Form 25 to remove the company’s common stock from listing and registration under Section 12(b) of the Exchange Act. Other 8-Ks describe corporate actions such as reverse stock splits, public offerings of common stock and warrants, and equity compensation grants of restricted stock units to directors and officers.
The Form 25 (Form 25-NSE) filed by Nasdaq is a key document confirming the removal of Petros’ common stock from listing and registration on the Nasdaq Stock Market LLC. While this filing affects exchange listing status, the company’s filings note that Petros remains subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act and that its shares continue to trade on an OTC market.
Stock Titan’s platform presents these SEC filings alongside AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex disclosures about listing status, discontinued operations, capital raises, and governance decisions. Users can review 10-K and 10-Q reports for broader context, 8-Ks for event-driven updates, and Form 4 insider transaction reports (when filed) to monitor equity awards and other changes in beneficial ownership related to Petros Pharmaceuticals.